1.0NHDhttps://nhdbio.com/cnNHDhttps://nhdbio.com/cnrich600338<blockquote class="wp-embedded-content" data-secret="jrxRhSmL5m"><a href="https://nhdbio.com/cn/status/aod-9604/">AOD-9604开发及复配现状</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://nhdbio.com/cn/status/aod-9604/embed/#?secret=jrxRhSmL5m" width="600" height="338" title="《AOD-9604的开发与配方现状》—NHD" data-secret="jrxRhSmL5m" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://nhdbio.com/wp-includes/js/wp-embed.min.js </script>FDA 在 2024 年 12 月的评估中，基于物质表征、有效性和安全性方面的局限，建议不将 AOD-9604 游离碱或醋酸盐加入 503A 原料药清单。这项评估针对配制药物用原料清单，并非产品批准审查，不应将两者混为一谈。